TT-00420

Tinengotinib · TransThera Sciences (Nanjing), Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for TT-00420, covering 2024-01-24 to 2024-06-25. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma [Phase 2]